Scientists have conducted a series of trials that point to various ways to check the progress of the disease
Last week, a US biotechnology company claimed to have produced the first drug with the ability to slow down the development of Alzheimer’s. Biogen says it hopes to release aducanumab on to the market after it gets US Food and Drug Administration approval, which could take up to two years. Research into the drug had been abandoned but trials using higher doses of the drug are claimed to improve cognitive functions such as memory, orientation, and language.
Continue reading...from The Guardian https://ift.tt/2BLcmWf
